Evidence map›Paper›PMID 34571965›Full record

ReviewCells2021

The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters.

Lucia Catani, Michele Cavo, Francesca Palandri

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Extracellular Vesicles in Haematological Disorders: A Friend or a Foe?International journal of molecular sciences · 2022
    Review
  6. Extracellular Vesicles in Myeloid Neoplasms.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Lucia CataniIRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, Institute of Hematology "Seràgnoli", University of Bologna, 40138 Bologna, Italy.ORCID 0000-0002-4650-201X
Michele CavoIRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, Institute of Hematology "Seràgnoli", University of Bologna, 40138 Bologna, Italy.
Francesca PalandriIRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology "Seràgnoli", 40138 Bologna, Italy.ORCID 0000-0001-8367-5668
University of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloproliferative Neoplasms (MPN) are acquired clonal disorders of the hematopoietic stem cells and include Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis. MPN are characterized by mutations in three driver genes (

Indexed as

Tumor MicroenvironmentAnimalsBiomarkers, TumorExtracellular VesiclesGene Expression Regulation, NeoplasticHumansInflammation MediatorsMyeloproliferative DisordersPolycythemia VeraPrimary MyelofibrosisSignal TransductionThrombocythemia, EssentialBiomarkers, TumorInflammation Mediatorsbiomarkeressential thrombocythemiaextracellular vesiclesinflammatory microenvironmentmyelofibrosismyeloproliferative neoplasmspolycythemia verathrombosis

Identifiers

PMID34571965
PMCPMC8464728
OpenAlexW3196908747

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.